Generic Semaglutide Is Everywhere Now. A Pharmacist’s Read on What Changed

In March 2026 the semaglutide patent expired in India, and the price of the most talked-about drug of the decade fell off a cliff. Twelve manufacturers now hold approval, selling under more than twenty brand names. A month’s supply that cost upward of nine thousand rupees at its peak is available in some formats for a few hundred.

I am a pharmacist. I have watched a lot of drugs go generic, and the pattern is always the same: access improves, which is genuinely good, and supervision collapses, which is not. The people who benefit most from a price fall are the people who could not afford appropriate treatment. The people harmed by it are the ones who were never going to see a prescriber at all, and who now do not have to.

This is what I would tell a client who came to me holding a screenshot of a ₹1,800 pen.

What actually changed

Semaglutide is a GLP-1 receptor agonist. Novo Nordisk sold it as Ozempic for type 2 diabetes and Wegovy for weight management. The Indian patent expired on 20 March 2026, and the Drugs Controller General of India has since approved a long list of generic versions — vials, prefilled pens, reusable pens, at wildly different price points.

The spread is the striking part. Branded Ozempic sat around ₹5,660 to ₹9,100 a month even after a substantial price cut. Wegovy ranged higher still. Generics now run from roughly ₹1,800 to ₹3,500 a month in prefilled-pen format, and the cheapest vial-based options are advertised at a fraction of that. That is close to a ninety percent fall in two years.

A price fall of that size does not just widen access. It changes who is taking the drug. When something costs nine thousand a month, people generally arrive at it through a doctor. When it costs eighteen hundred, they arrive at it through Instagram.

It is still Schedule H, and that is not paperwork

Every one of these brands is a Schedule H drug. It can only be dispensed against a valid prescription from a registered medical practitioner. It cannot legally be sold over the counter, and the sellers offering it without one are not doing you a favour.

The prescription is not a formality standing between you and your weight loss. It is the step where somebody checks whether you have a personal or family history of medullary thyroid carcinoma or MEN 2, whether you have had pancreatitis, whether you have gastroparesis or significant reflux, whether you are pregnant or planning to be, what else you take, and — if you have diabetes — whether your other medicines need adjusting downward before you start. Several of those are absolute reasons not to take it. None of them are visible to a seller on a messaging app.

If you have diabetes and you add a GLP-1 on top of insulin or a sulfonylurea without anyone adjusting the doses, the risk is hypoglycaemia, and it is not theoretical.

What the drug does, and what it does not

Semaglutide slows gastric emptying and acts on appetite regulation centrally. You feel full sooner, you stay full longer, and the persistent food noise that makes a calorie deficit exhausting gets quieter. That is the whole mechanism, and it is a good one — the effect sizes in the trials are real and larger than anything lifestyle advice alone produces at population level.

What it is not: it is not a fat burner, it does not raise your metabolic rate, and it does not choose which tissue you lose. It creates a deficit by making you eat less. Everything that was true about how you eat in a deficit is still true — you have just been given help holding the deficit.

And it does not fix the thing underneath. Appetite regulation reverts when the drug stops. Trial data on discontinuation is consistent and unflattering: most of the weight comes back, along with the cardiometabolic markers that improved. That is not a failure of the drug, it is what a treatment for a chronic condition does when you stop treating. But it means the question to answer before starting is not “will this work” — it will — it is “what is my plan for month eighteen”.

The muscle problem nobody puts in the advertisement

This is the part I care most about, and it is the part that is almost never mentioned in the marketing.

In rapid weight loss, a meaningful share of what you lose is lean mass, not fat — commonly cited in the region of a quarter to nearly half of total weight lost, depending on the population and how hard the deficit is. Semaglutide produces rapid weight loss very reliably, in people who are eating substantially less protein than before, and who in most cases are not lifting anything.

That combination has a name and a bad ending: you get lighter, smaller, weaker, and metabolically worse off per kilogram than you started. Then you stop the drug, appetite returns, and the weight comes back as fat onto a smaller muscle base. This is how people end up heavier in body fat percentage at a lower body weight than before they began.

It is avoidable, and the two things that avoid it are unglamorous:

• Protein has to go up as a proportion of a smaller intake, not stay flat. This is harder than it sounds when the drug has removed your appetite and food has become mildly unappealing. It usually requires deliberate structuring rather than eating intuitively.
• Resistance training is not optional on a GLP-1. It is the signal that tells the body to preserve muscle in a deficit. If you have never trained, this is where to begin.

Older adults and anyone with the South Asian phenotype — relatively low muscle mass and higher visceral fat at a given BMI — have less lean mass to spare in the first place, which makes this more urgent, not less.

Where the vials go wrong

The cheapest generics are vials, and vials are where a pharmacist starts worrying.

A prefilled pen delivers a defined dose when you turn the dial. A vial requires somebody to measure a small volume of a potent drug into a syringe, correctly, every week, with no built-in safeguard. Dosing errors with vial-based GLP-1s are well documented and they are not small errors — the reported cases are typically several-fold overdoses, because people confuse the units marked on an insulin syringe with milligrams of drug. The consequence is severe vomiting and dehydration, sometimes hospital admission.

I am deliberately not printing conversion instructions here, because that is exactly the decision that should be made by the person prescribing and the pharmacist dispensing to you, with your specific product in front of them. If you have been given a vial and you are not completely certain what you are drawing up, do not guess and do not ask the internet. Take the vial to a pharmacy.

Two further things about the cheap end of the market. Cold chain: semaglutide is refrigerated, and a product that has spent a week in a courier bag in an Indian summer is not the product you paid for. Provenance: unlabelled or compounded “research” peptide sold through social channels is not a regulated generic, whatever the price comparison suggests. Buy a DCGI-approved brand, from a licensed pharmacy, with a batch number and an expiry on the carton.

Side effects: the ones that pass, and the ones that do not

Nausea, reflux, constipation, early fullness and burping are common, usually worst in the first weeks after each dose increase, and usually settle. They are also worse if you eat the way you ate before — large portions, high fat, late at night — on a stomach that is now emptying slowly.

The ones that need a doctor rather than patience: severe persistent abdominal pain radiating to the back, especially with vomiting, which needs pancreatitis excluded the same day; vomiting severe enough that you cannot keep fluids down; and any new lump in the neck or difficulty swallowing. Gallstones are more common with rapid weight loss from any cause, this included. Constipation is common enough that fibre and fluid should be planned for rather than reacted to — the gut side of this is worth getting ahead of.

One that is easy to miss: if you also take metformin, the combination is common and sensible, but long-term metformin depletes B12 and almost nobody tests for it. I have written about that specific gap separately.

Who this is genuinely right for

People with type 2 diabetes, for whom this class has cardiovascular and renal evidence behind it and is a legitimate first-line consideration. People with obesity and a related complication — sleep apnoea, fatty liver with fibrosis, joint disease, insulin resistance in PCOS — where the risk of staying where they are is higher than the risk of the drug. People who have made honest, sustained attempts at a deficit and found appetite to be the thing that defeats them every time. That last group is large, and telling them to try harder has never once worked.

Who it is not for: someone with ten kilograms to lose who has never seriously structured their eating, wants it gone before a wedding, and intends to stop afterwards. That person will lose the weight, lose muscle with it, stop, regain, and conclude their metabolism is broken. It was not, before.

What to take away

• The patent expiry has cut the price by roughly ninety percent, which improves access and removes the accidental gatekeeping that used to route people through a doctor
• It remains Schedule H. The prescription step is where genuine contraindications get caught and where existing diabetes medicines get adjusted
• The drug reduces appetite. It does not decide what you lose, and stopping reverses the appetite effect
• Protein and resistance training are what keep the loss from being half muscle. On a GLP-1 they are part of the treatment, not an optional extra
• Vials are where serious dosing errors happen. Get the first dose drawn up or demonstrated by a pharmacist, and check cold chain and provenance before you buy anything cheap
• Persistent severe abdominal pain with vomiting is a same-day medical problem, not a side effect to push through

Before you act on any of this

I am a pharmacist and a nutritionist. I am not your doctor, I do not prescribe, and nothing in this article is a recommendation to start, stop, switch or adjust semaglutide or any other medicine — those are decisions for the clinician treating you, who knows your history and your other prescriptions. This article does not contain dosing instructions and is not a substitute for the counselling you should receive when the drug is dispensed. If you have diabetes, do not add or change anything without your prescriber reviewing your existing medicines first. What I can do is help you build the eating and training around the treatment so that what you lose is fat and what you keep is muscle — that starts with a one-time assessment.